Compare NVR Inc. Common Stock (NVR) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NVR Inc. Common Stock vs Philip Morris International Inc. — how do they compare? NVR Inc. Common Stock trades at $5,750 (market cap $15.45B), while Philip Morris International Inc. trades at $209 (market cap $310.62B). The key difference: Philip Morris International Inc. is far larger — about 20.1× NVR Inc. Common Stock's market cap, and Philip Morris International Inc. pays a 3.21% dividend while NVR Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold NVR Inc. Common Stock for 0 Days and Philip Morris International Inc. for 85 Days on average.
| NVR | PM | |
|---|---|---|
Market Cap | $15.45B | $310.62B |
Volume | 53,419 | 4,145,126 |
Sector | Consumer Cyclical | Consumer Staples |
52-Week High | $8.10K | $205.58 |
52-Week Low | $5.56K | $144.33 |
Typical Hold Time | 0 Days | 85 Days |
Enterprise Value | $15.36B | $353.73B |
Dividend Yield | — | 3.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVR trades at $5,797.61, up 0.83% today, with a P/E of 15.07 and P/S of 1.79. Recent earnings missed estimates in Q1 and Q2 2026, with revenue and net income projected to decline in 2026. The stock faces headwinds from margin pressure and softer homebuyer demand, as highlighted by Zacks naming it Bear of the Day on October 9, 2026. Despite this, strong profitability metrics like a 31.54% ROE and consistent cash flow from operations support its financial resilience.
The outlook is cautious due to earnings misses and a projected revenue drop, but the asset-light model and share buybacks provide stability. Risks include mortgage rate sensitivity and competitive pressures, while analyst consensus leans neutral with a $6,550 price target. Patient investors may find value if housing demand recovers.
Philip Morris International (PM) trades at $199.29, down 1.34% on the day, with strong earnings momentum after beating Q1 and Q2 2026 EPS estimates. The company shows robust fundamentals with 2025 revenue of $40.65B and net income margin of 25.56%, though valuation ratios appear elevated. Technical indicators show a bullish moving average trend but overbought RSI signals, with key support at $199. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now representing over 40% of revenue.
PM's outlook remains positive with analyst consensus price target of $212.17 (6.5% upside) and 68% buy ratings. Growth is driven by smoke-free product adoption and international expansion, but risks include regulatory pressures, high debt levels, and premium valuation. The stock offers dividend income with recent $1.60 payout, supporting total return potential for investors comfortable with tobacco sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NVR Inc. Common Stock
NVR Inc. is a homebuilder operating through homebuilding and mortgage banking segments, building single-family homes, townhomes, and condominiums under the Ryan Homes, NVHomes, and Heartland Homes brands. It uses a land-light model, acquiring lots through third-party option agreements rather than holding large land inventories, and provides mortgage and title services through NVR Mortgage.
Read more on NVR →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
